[{"id":"06e22114-2e9b-44ef-aeef-5965af238d91","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014762","created_at":"2023-08-28T14:08:43.980Z","updated_at":"2024-07-02T16:34:59.518Z","phase":"Phase 1","brief_title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","source_id_and_acronym":"NCT06014762","lead_sponsor":"Poseida Therapeutics, Inc.","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG6540 • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2041","study_completion_date":" 03/01/2041","last_update_posted":"2024-06-03"}]